Recital 216, Commission Decision of 12/12/2023 declaring a concentration to be compatible with the co…

In forcesince 12 Dec 2023

Given the breadth of what can be considered as biotechnology or bio-solutions,

based on the internal documents of the Parties and initial market feedback, the 307 eRFI to customers, reply to Question H.5. 308 Non-confidential minutes, call with customer, 6 June 2023, 11:00 – 12:00 CET. 309 eRFI to competitors, reply to Question H.5. 310 eRFI to customers, reply to Question H.1. 311 Press release announcing Transaction: https://mleu.globenewswire.com/Resource/Download/0b23bd5b-590b-4601-bf11-88d9e77b2b3a (last accessed 29 November 2023). 312 Non-confidential minutes, call with competitor, 26 April 2023, 14:00 – 15:00 CET.

Commission identified the following industry segments as a relevant segmentation upon which to undertake its assessment: (i) Food & Beverage (“F&B”); (ii) Human Health; (iii) Animal Health; (iv) Industrial Applications; (v) Household Care and (vi) Bio Agricultural (“BioAg”) solutions.313 The Commission in particular focused on the F&B segment, where the Parties are particularly strong players, both for marketed products and innovation.